Vamil Divan
Stock Analyst at Guggenheim
(4.81)
# 63
Out of 5,182 analysts
256
Total ratings
67.74%
Success rate
21.88%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $54 → $56 | $40.81 | +37.22% | 10 | Apr 24, 2026 | |
| ABBV AbbVie | Maintains: Buy | $242 → $249 | $197.38 | +26.15% | 29 | Apr 10, 2026 | |
| AMGN Amgen | Maintains: Neutral | $347 → $351 | $340.18 | +3.18% | 3 | Apr 9, 2026 | |
| ASMB Assembly Biosciences | Maintains: Buy | $39 → $43 | $27.52 | +56.25% | 3 | Apr 6, 2026 | |
| UNCY Unicycive Therapeutics | Maintains: Buy | $46 → $40 | $7.23 | +453.25% | 2 | Apr 2, 2026 | |
| PFE Pfizer | Maintains: Buy | $35 → $36 | $26.79 | +34.38% | 24 | Mar 24, 2026 | |
| JBIO Jade Biosciences | Maintains: Buy | $17 → $23 | $26.64 | -13.66% | 3 | Mar 11, 2026 | |
| MRK Merck & Co. | Maintains: Buy | $122 → $140 | $110.23 | +27.01% | 15 | Feb 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $225.34 | +6.51% | 19 | Jan 23, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $115 → $124 | $79.60 | +55.78% | 14 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $221 | $135.98 | +62.52% | 8 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $8 | $3.46 | +131.21% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.00 | +200.00% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $11 | $5.16 | +113.18% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $5.49 | +136.79% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $1.86 | +276.34% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $4.85 | +106.19% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $37.28 | +63.63% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $11.01 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $7.03 | +269.84% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.35 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.30 | -14.80% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $128.04 | -23.46% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $33.73 | +0.80% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.91 | +243.64% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $187.40 | -73.85% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $868.27 | -59.00% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.12 | -1.96% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $9.59 | +1,505.84% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $5.22 | +187.36% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.55 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $31.26 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $15.92 | -5.78% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $57.78 | +5.57% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.91 | +5,292.67% | 3 | Jan 17, 2018 |
Travere Therapeutics
Apr 24, 2026
Maintains: Buy
Price Target: $54 → $56
Current: $40.81
Upside: +37.22%
AbbVie
Apr 10, 2026
Maintains: Buy
Price Target: $242 → $249
Current: $197.38
Upside: +26.15%
Amgen
Apr 9, 2026
Maintains: Neutral
Price Target: $347 → $351
Current: $340.18
Upside: +3.18%
Assembly Biosciences
Apr 6, 2026
Maintains: Buy
Price Target: $39 → $43
Current: $27.52
Upside: +56.25%
Unicycive Therapeutics
Apr 2, 2026
Maintains: Buy
Price Target: $46 → $40
Current: $7.23
Upside: +453.25%
Pfizer
Mar 24, 2026
Maintains: Buy
Price Target: $35 → $36
Current: $26.79
Upside: +34.38%
Jade Biosciences
Mar 11, 2026
Maintains: Buy
Price Target: $17 → $23
Current: $26.64
Upside: -13.66%
Merck & Co.
Feb 6, 2026
Maintains: Buy
Price Target: $122 → $140
Current: $110.23
Upside: +27.01%
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $225.34
Upside: +6.51%
ANI Pharmaceuticals
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $79.60
Upside: +55.78%
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $135.98
Upside: +62.52%
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $3.46
Upside: +131.21%
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.00
Upside: +200.00%
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.16
Upside: +113.18%
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $5.49
Upside: +136.79%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $1.86
Upside: +276.34%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $4.85
Upside: +106.19%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $37.28
Upside: +63.63%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $11.01
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $7.03
Upside: +269.84%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.35
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.30
Upside: -14.80%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $128.04
Upside: -23.46%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $33.73
Upside: +0.80%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.91
Upside: +243.64%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $187.40
Upside: -73.85%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $868.27
Upside: -59.00%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.12
Upside: -1.96%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $9.59
Upside: +1,505.84%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $5.22
Upside: +187.36%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $28.55
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $31.26
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $15.92
Upside: -5.78%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $57.78
Upside: +5.57%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.91
Upside: +5,292.67%